haemophilus influenzae type b-neisseria meningitidis serogroups c and y-tetanus-toxoid conjugate vaccine
Vaccineexperimental
Clinical trial activity
14 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
12
Phase 3
6
Phase 4
2
Earliest trial started Mar 1, 2002 (NCT00135486)
Timeline
Indications
Approved for
Studied for
- Bacterial Infections · Phase 3
- Diphtheria · Phase 3
- Diphtheria-Tetanus-Pertussis Vaccine · Phase 3
- Haemophilus Infections · Phase 4
- Haemophilus influenzae type b · Phase 3
- Hepatitis A virus · Phase 4
- Hepatitis B · Phase 3
- Meningococcal Infections · Phase 3
- Neisseria meningitidis · Phase 3
- Pertussis Vaccine · Phase 3
- Streptococcal Infections · Phase 2
- Tetanus · Phase 3
- Virus Diseases · Phase 3
Mechanism of action
- Tetanus toxinImmunity, active
tetX immunity, active
- Neisseria meningitidisImmunity, active
Neisseria meningitidis immunity, active
- Haemophilus influenzaeImmunity, active
Haemophilus influenzae immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- haemophilus influenzae type b-neisseria meningitidis serogroups c and y-tetanus-toxoid conjugate vaccine
- haemophilus influenzae-type b polysaccharide-neisseria meningitidis outer membrane protein conjugate vaccine
- hib-menac-tt
- hib-mency-tt vaccine
- hibmency-tt vaccine
- hib-nomp
- menhibrix
- menhibrix
- pedvaxhib
- pedvaxhib
- polyribosylribitol phosphate from haemophilus influenzae type b as prp-ompc / outer membrane protein complex of neisseria meningitidis (outer membrane protein complex of the b11 strain of neisseria meningitidis subgroup b) / adsorbed hepatitis b surface antigen produced in recombinant yeast cells (saccharomyces cerevisiae)
- prp-ompc
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04978818 | Phase 4 | Nov 15, 2021 | Johns Hopkins University, Merck |
| NCT01978093 | Phase 3 | Feb 1, 2014 | GlaxoSmithKline |
| NCT01545375 | Phase 2 | May 1, 2012 | GlaxoSmithKline |
| NCT01337167 | Phase 3 | Apr 1, 2011 | Merck, Sanofi-Aventis |
| NCT00614614 | Phase 3 | Feb 1, 2008 | GlaxoSmithKline |
| NCT00345683 | Phase 3 | Jul 1, 2007 | GlaxoSmithKline |
| NCT00289913 | Phase 4 | Apr 1, 2006 | Merck |
| NCT00289783 | Phase 3 | Feb 1, 2006 | GlaxoSmithKline |
| NCT00228917 | Phase 3 | Jun 1, 2005 | GlaxoSmithKline |
| NCT00134719 | Phase 2 | Apr 1, 2005 | GlaxoSmithKline |
| NCT00127855 | Phase 2 | Mar 1, 2003 | GlaxoSmithKline |
| NCT00129116 | Phase 2 | Mar 1, 2003 | GlaxoSmithKline |
| NCT00135564 | Phase 2 | Jan 1, 2003 | GlaxoSmithKline |
| NCT00135486 | Phase 2 | Mar 1, 2002 | GlaxoSmithKline |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 11 | 11 | 2 | 2002 |
| Merck | For profit | 3 | 2 | 2 | 2006 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Sanofi-Aventis | For profit | 1 | 0 | 1 | 2011 |
4 organizations
Page 1 / 1